Vaxcyte, Inc. $PCVX Shares Sold by Renaissance Technologies LLC

Renaissance Technologies LLC decreased its position in Vaxcyte, Inc. (NASDAQ:PCVX) by 16.1% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 54,734 shares of the company’s stock after selling 10,477 shares during the quarter. Renaissance Technologies LLC’s holdings in Vaxcyte were worth $3,181,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently bought and sold shares of PCVX. Smartleaf Asset Management LLC lifted its stake in Vaxcyte by 156.2% during the fourth quarter. Smartleaf Asset Management LLC now owns 597 shares of the company’s stock valued at $27,000 after purchasing an additional 364 shares during the last quarter. Caitong International Asset Management Co. Ltd grew its holdings in shares of Vaxcyte by 1,463.4% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 641 shares of the company’s stock worth $30,000 after acquiring an additional 600 shares during the last quarter. EverSource Wealth Advisors LLC raised its position in shares of Vaxcyte by 33.0% during the fourth quarter. EverSource Wealth Advisors LLC now owns 741 shares of the company’s stock worth $34,000 after purchasing an additional 184 shares during the period. CIBC Private Wealth Group LLC lifted its holdings in shares of Vaxcyte by 22,500.0% during the third quarter. CIBC Private Wealth Group LLC now owns 1,356 shares of the company’s stock valued at $49,000 after purchasing an additional 1,350 shares during the last quarter. Finally, Capital Advisors Ltd. LLC purchased a new stake in shares of Vaxcyte during the first quarter valued at $58,000. 96.78% of the stock is owned by institutional investors and hedge funds.

Vaxcyte Trading Down 1.4%

Shares of PCVX stock opened at $58.07 on Friday. The company has a market capitalization of $8.39 billion, a price-to-earnings ratio of -7.61 and a beta of 1.23. Vaxcyte, Inc. has a 1-year low of $29.29 and a 1-year high of $65.00. The stock’s fifty day simple moving average is $53.85 and its 200-day simple moving average is $55.21.

Vaxcyte (NASDAQ:PCVX) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($1.97) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.06) by $0.09. During the same period in the previous year, the company earned ($1.22) earnings per share. On average, sell-side analysts predict that Vaxcyte, Inc. will post -7.82 EPS for the current year.

Insider Activity at Vaxcyte

In other Vaxcyte news, COO Jim Wassil sold 2,250 shares of the company’s stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $53.86, for a total value of $121,185.00. Following the transaction, the chief operating officer owned 157,541 shares in the company, valued at approximately $8,485,158.26. This represents a 1.41% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew Guggenhime sold 10,000 shares of the stock in a transaction that occurred on Monday, August 3rd. The stock was sold at an average price of $53.89, for a total transaction of $538,900.00. Following the completion of the sale, the chief financial officer owned 105,176 shares of the company’s stock, valued at approximately $5,667,934.64. The trade was a 8.68% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 120,646 shares of company stock valued at $6,570,810 over the last ninety days. 3.30% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several analysts have issued reports on PCVX shares. Weiss Ratings restated a “sell (d-)” rating on shares of Vaxcyte in a report on Monday, July 6th. Zacks Research downgraded shares of Vaxcyte from a “hold” rating to a “strong sell” rating in a research report on Tuesday, July 14th. Finally, Wall Street Zen upgraded shares of Vaxcyte from a “strong sell” rating to a “sell” rating in a report on Saturday. Five investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, Vaxcyte has a consensus rating of “Hold” and a consensus target price of $86.00.

Vaxcyte Company Profile

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.